NEW YORK (GenomeWeb) – German molecular diagnostics firm Curetis and BGI Group subsidiary MGI said today they plan to codevelop next-generation sequencing-based in vitro diagnostic assays for microbial infections.

The two firms have signed a broad memorandum of understanding to develop IVD assays targeting an array of pathogens and genetic and antibiotic resistance markers. The firms plan to combine Curetis' PCR platform, the Unyvero L4 Lysator, with MGI's SP100 Sample Preparation System and MGISeq NGS sequencers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jun
05
Sponsored by
Linguamatics

This webinar will discuss how Sanofi used literature mining to annotate the association of human leukocyte antigen (HLA) alleles with diseases and drug hypersensitivity as part of a multiple sclerosis (MS) biomarker discovery project.

Jun
14
Sponsored by
Sophia Genetics

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
26
Sponsored by
Lexogen

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.